1
|
Battiston K, Parrag I, Statham M, Louka D, Fischer H, Mackey G, Daley A, Gu F, Baldwin E, Yang B, Muirhead B, Hicks EA, Sheardown H, Kalachev L, Crean C, Edelman J, Santerre JP, Naimark W. Polymer-free corticosteroid dimer implants for controlled and sustained drug delivery. Nat Commun 2021; 12:2875. [PMID: 34001908 PMCID: PMC8129133 DOI: 10.1038/s41467-021-23232-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Accepted: 04/08/2021] [Indexed: 12/30/2022] Open
Abstract
Polymeric drug carriers are widely used for providing temporal and/or spatial control of drug delivery, with corticosteroids being one class of drugs that have benefitted from their use for the treatment of inflammatory-mediated conditions. However, these polymer-based systems often have limited drug-loading capacity, suboptimal release kinetics, and/or promote adverse inflammatory responses. This manuscript investigates and describes a strategy for achieving controlled delivery of corticosteroids, based on a discovery that low molecular weight corticosteroid dimers can be processed into drug delivery implant materials using a broad range of established fabrication methods, without the use of polymers or excipients. These implants undergo surface erosion, achieving tightly controlled and reproducible drug release kinetics in vitro. As an example, when used as ocular implants in rats, a dexamethasone dimer implant is shown to effectively inhibit inflammation induced by lipopolysaccharide. In a rabbit model, dexamethasone dimer intravitreal implants demonstrate predictable pharmacokinetics and significantly extend drug release duration and efficacy (>6 months) compared to a leading commercial polymeric dexamethasone-releasing implant.
Collapse
Affiliation(s)
| | - Ian Parrag
- Ripple Therapeutics, Toronto, ON, Canada
| | | | | | | | | | - Adam Daley
- Ripple Therapeutics, Toronto, ON, Canada
| | - Fan Gu
- Ripple Therapeutics, Toronto, ON, Canada
| | | | | | - Ben Muirhead
- School of Biomedical Engineering, McMaster University, Hamilton, ON, Canada
| | - Emily Anne Hicks
- Department of Chemical Engineering, McMaster University, Hamilton, ON, Canada
| | - Heather Sheardown
- School of Biomedical Engineering, McMaster University, Hamilton, ON, Canada
- Department of Chemical Engineering, McMaster University, Hamilton, ON, Canada
| | - Leonid Kalachev
- Department of Mathematical Sciences, University of Montana, Missoula, MT, USA
| | | | | | - J Paul Santerre
- Ripple Therapeutics, Toronto, ON, Canada
- Faculty of Dentistry, University of Toronto, Toronto, ON, Canada
- Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada
- Translational Biology and Engineering Program, Ted Rogers Centre for Heart Research, Toronto, ON, Canada
| | | |
Collapse
|
2
|
Chatterjee A, Mirer PL, Zaldivar Santamaria E, Klapperich C, Sharon A, Sauer-Budge AF. RNA Isolation from Mammalian Cells Using Porous Polymer Monoliths: An Approach for High-Throughput Automation. Anal Chem 2010; 82:4344-56. [DOI: 10.1021/ac100063f] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Affiliation(s)
- Anirban Chatterjee
- Departments of Mechanical Engineering and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, and Center for Manufacturing Innovation, Fraunhofer USA, Brookline, Massachusetts 02446
| | - Paul L. Mirer
- Departments of Mechanical Engineering and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, and Center for Manufacturing Innovation, Fraunhofer USA, Brookline, Massachusetts 02446
| | - Elvira Zaldivar Santamaria
- Departments of Mechanical Engineering and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, and Center for Manufacturing Innovation, Fraunhofer USA, Brookline, Massachusetts 02446
| | - Catherine Klapperich
- Departments of Mechanical Engineering and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, and Center for Manufacturing Innovation, Fraunhofer USA, Brookline, Massachusetts 02446
| | - Andre Sharon
- Departments of Mechanical Engineering and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, and Center for Manufacturing Innovation, Fraunhofer USA, Brookline, Massachusetts 02446
| | - Alexis F. Sauer-Budge
- Departments of Mechanical Engineering and Biomedical Engineering, Boston University, Boston, Massachusetts 02215, and Center for Manufacturing Innovation, Fraunhofer USA, Brookline, Massachusetts 02446
| |
Collapse
|
3
|
Rosengren L, Simko H, Aryan L, Axelsson-Lendin P, Chmielewska J, Mode A, Parrow V. Antisense and sense RNA probe hybridization to immobilized crude cellular lysates: a tool to screen growth hormone antagonists. ACTA ACUST UNITED AC 2005; 10:260-9. [PMID: 15809322 DOI: 10.1177/1087057104273802] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The growth-promoting effect of growth hormone (GH) is primarily mediated by insulin-like growth factor-1 (IGF-1). The liver is the main source of circulating IGF-I. The authors have used rodent primary hepatocytes for studies on pharmacological intervention of IGF-I mRNA expression. A 96-well nonradioactive IGF-1 mRNA quantification assay was developed, based on the hybridization of sense and antisense RNA probes, to replicate membranes with crude hepatocyte lysates. The sense hybridization was used as an internal standard. The antagonistic properties of a set of GH-receptor binding compounds were evaluated. Two compounds were found to down-regulate IGF-I mRNA. Effects due to metabolic inhibition or toxicity were excluded using a cell proliferation assay. To investigate potential unspecific transcriptional effects, the mRNA levels of the housekeeping genes, beta-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), were determined. Two other GH-regulated genes, cytochrome P450 2C12 (CYP2C12) and a rat homologue to the human alpha1B-glycoprotein (A1BG), were quantified by RNase protection assays and found to be down-regulated, confirming the antagonistic property of 1 compound. In conclusion, a direct filter hybridization assay of hepatocyte lysates using nonradioactive sense and antisense probes can be used for quantitative mRNA measurements and could constitute a valuable tool in screening for pharmacologically active compounds.
Collapse
Affiliation(s)
- Linda Rosengren
- Department of Assay Development & Screening, Biovitrum AB, 17176 Stockholm, Sweden.
| | | | | | | | | | | | | |
Collapse
|